
Hoth Therapeutics (HOTH) Stock Forecast & Price Target
Hoth Therapeutics (HOTH) Analyst Ratings
Bulls say
Hoth Therapeutics is poised for success with its strong pipeline addressing unmet medical needs in the areas of cancer, skin toxicities, Alzheimer's, and obesity. The company is making significant progress in preclinical and clinical development, with key milestones such as IND submissions and potential partnerships on the horizon. However, investors should also be aware of potential risks, including regulatory and financial risks, when considering investment opportunities with Hoth Therapeutics.
Bears say
Hoth Therapeutics is currently focusing on developing multiple treatments for various medical needs such as cancer, mast-cell derived cancers and anaphylaxis, Alzheimer's, and obesity. However, despite positive data on its HT-001 drug, the lack of controlled clinical evidence and detailed efficacy information raises concern about the company's ability to successfully bring any of its treatments to market, especially with potential risks such as clinical/regulatory and financial challenges. Without clear validation, investors may find the stock too risky to invest in.
This aggregate rating is based on analysts' research of Hoth Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Hoth Therapeutics (HOTH) Analyst Forecast & Price Prediction
Start investing in Hoth Therapeutics (HOTH)
Order type
Buy in
Order amount
Est. shares
0 shares